History

May 2017: ViraTherapeutics appoints Dr. Heinz Schwer as CEO

ViraTherapeutics announces the appointment of Dr. Heinz Schwer as CEO. He takes over the position from interim CEO and co-founder Prof. Dr. Dorothee von Laer, who will remain a scientific advisor.

 

May 2017: Grand opening of Christian Doppler Laboratory for viral immunotherapy of cancer at the Medical University of Innsbruck

ViraTherapeutics and Boehringer Ingelheim partner with the Medical University of Innsbruck in the new Christian Doppler Laboratory for cancer viro-immunotherapy. Generous funding is provided by the Christian Doppler Research Association.

 

September 2016: ViraTherapeutics and Boehringer Ingeheim announce long-term collaboration

ViraTherapeutics and Boehringer Ingelheim announce a new long-term collaboration to develop a next generation oncolytic virus platform and the lead candidate VSV-GP. The potential transaction value is up to EUR 210 million and includes co-funding of development activities and an option to acquire ViraTherapeutics.

 

August 2016: Closing of Series B financing round

ViraTherpeutics raises 4.1 million Euro in a series B financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF), EMBL Ventures, Empl Privatstiftung and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.

 

November 2015: ViraTherapeutics inaugurates new laboratory in Innsbruck

ViraTherpeutics inaugurates new facilities in Innsbruck comprising laboratory and office space for its R&D and management staff.

 

June 2015: Closing of Series A financing round

ViraTherapeutics raises 5.2 million Euro in a series A financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and EMBL Ventures, and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.

 

December 2014: ViraTherapeutics receives Research Studio Austria grant

The financing was awarded by the Austrian Research Promoting Agency (FFG). In the Research Studio Austria "ViraVet" ViraTherapeutics will collaborate with the verterinary faculties of the universities of Vienna and Munich.

 

November 2014: ViraTherapeutics receives Seedfinancing grant from aws

The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.

 

July 2013: ViraTherapeutics wins 2nd prize of Science4Life Venture Cup

The second prize of the Science4Life Venture Cup 2013 was awarded to ViraTherapeutics.

 

June 2013: European patent granted for VSV-GP technology

A patent protecting ViraTherapeutics' proprietary oncolytic virus platform was granted by the European Patent Office. In the past, the patent has already been granted in other contries.

 

April 2013: ViraTherapeutics founded as a GmbH

ViraTherapeutics was founded as a GmbH in Innsbruck, Austria. All patents and patent applications have been transferred to ViraTherapeutics.

 

January 2013: ViraTherapeutics receives preseed grant from aws

The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.

 

October 2012: ViraTherapeutics wins Best of Biotech

ViraTherapeutics business concept won the first prize of the international Life Science business plan competition "Best of Biotech".

 

October 2012: ViraTherapeutics wins Tyrolean Innovation Award

ViraTherapeutics' business concept was awarded with the "Innovation Award" of the Tyrolean Chamber of Commerce in the category "Best Concept".

 

June 2012: ViraTherapeutics wins 1st prize of AdventureX

ViraTherapeutics business concept won the 1st prize of the Tyrolean business plan competition "AdventureX".

Druckversion Druckversion | Sitemap
© ViraTherapeutics GmbH